{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:43:48Z","timestamp":1794368628540,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0512-6","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:04:24Z","timestamp":1556625864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-8181","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"2","key":"512_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108. \n                    https:\/\/doi.org\/10.3322\/caac.21262\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"512_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267\u201382. \n                    https:\/\/doi.org\/10.1097\/PAP.0b013e3181b4fffa\n                    \n                  .","journal-title":"Adv Anat Pathol"},{"issue":"8","key":"512_CR3","doi-asserted-by":"publisher","first-page":"081412","DOI":"10.1117\/1.JBO.17.8.081412","volume":"17","author":"S Kaja","year":"2012","unstructured":"Kaja S, Hilgenberg JD, Collins JL, Shah AA, Wawro D, Zimmerman S, Magnusson R, Koulen P. Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. J Biomed Opt. 2012;17(8):081412\u20131. \n                    https:\/\/doi.org\/10.1117\/1.JBO.17.8.081412\n                    \n                  .","journal-title":"J Biomed Opt"},{"issue":"24","key":"512_CR4","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519\u201329. \n                    https:\/\/doi.org\/10.1056\/NEJMra041842\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"328","key":"512_CR5","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aad7118\n                    \n                  .","journal-title":"Sci Transl Med"},{"issue":"5","key":"512_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372.","journal-title":"Int Immunol"},{"issue":"8","key":"512_CR7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","volume":"20","author":"M Gato-Canas","year":"2017","unstructured":"Gato-Canas M, Zuazo M, Arasanz H, Ibanez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818\u201329. \n                    https:\/\/doi.org\/10.1016\/j.celrep.2017.07.075\n                    \n                  .","journal-title":"Cell Rep"},{"issue":"4","key":"512_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. \n                    https:\/\/doi.org\/10.1038\/nrc3239\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"512_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800. \n                    https:\/\/doi.org\/10.1038\/nm730\n                    \n                  .","journal-title":"Nat Med"},{"issue":"5","key":"512_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275\u201387. \n                    https:\/\/doi.org\/10.1038\/nrc.2016.36\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"512_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. J Clin Pathol. 2018;71(3):189\u201394. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2017-204853\n                    \n                  .","journal-title":"J Clin Pathol"},{"issue":"9","key":"512_CR12","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360\u20135. \n                    https:\/\/doi.org\/10.1073\/pnas.0611533104\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"512_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/PGP.0000000000000494","volume":"38","author":"Anne M. Mills","year":"2019","unstructured":"Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM. Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: a study of PD-L1 and IDO in 112 cases from the African American Cancer epidemiology study (AACES). Int J Gynecol Pathol. 2018. \n                    https:\/\/doi.org\/10.1097\/PGP.0000000000000494\n                    \n                  .","journal-title":"International Journal of Gynecological Pathology"},{"issue":"7","key":"512_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1000097\n                    \n                  .","journal-title":"PLoS Med"},{"issue":"3","key":"512_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/ije\/dyp157","volume":"39","author":"MD Coory","year":"2010","unstructured":"Coory MD. Comment on: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2010;39(3):932; author reply 933. \n                    https:\/\/doi.org\/10.1093\/ije\/dyp157\n                    \n                  .","journal-title":"Int J Epidemiol"},{"issue":"7414","key":"512_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. \n                    https:\/\/doi.org\/10.1136\/bmj.327.7414.557\n                    \n                  .","journal-title":"BMJ"},{"issue":"9","key":"512_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","volume":"127","author":"J Lau","year":"1997","unstructured":"Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820\u20136.","journal-title":"Ann Intern Med"},{"issue":"7109","key":"512_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"8","key":"512_CR19","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1097\/IGC.0000000000001334","volume":"28","author":"Xinxin Zhu","year":"2018","unstructured":"Zhu X, Zhao L, Lang J. The BRCA1 methylation and PD-L1 expression in sporadic ovarian Cancer. Int J Gynecol Cancer. 2018. \n                    https:\/\/doi.org\/10.1097\/IGC.0000000000001334\n                    \n                  .","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"1","key":"512_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13048-018-0414-z","volume":"11","author":"ML Drakes","year":"2018","unstructured":"Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, Joyce C, O'Brien TE, Stack MS, Stiff PJ. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J Ovarian Res. 2018;11(1):43. \n                    https:\/\/doi.org\/10.1186\/s13048-018-0414-z\n                    \n                  .","journal-title":"J Ovarian Res"},{"issue":"12","key":"512_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3760\/cma.j.issn.0529-567x.2017.12.008","volume":"52","author":"MJ Li","year":"2017","unstructured":"Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH. Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma. Zhonghua Fu Chan Ke Za Zhi. 2017;52(12):835\u201343. \n                    https:\/\/doi.org\/10.3760\/cma.j.issn.0529-567x.2017.12.008\n                    \n                  .","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"issue":"6","key":"512_CR22","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e77","volume":"28","author":"J Zhu","year":"2017","unstructured":"Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017;28(6):e77. \n                    https:\/\/doi.org\/10.3802\/jgo.2017.28.e77\n                    \n                  .","journal-title":"J Gynecol Oncol"},{"key":"512_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.intimp.2017.08.017","volume":"52","author":"Q Wang","year":"2017","unstructured":"Wang Q, Lou W, Di W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017;52:7\u201314. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2017.08.017\n                    \n                  .","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"512_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-017-0304-9","volume":"10","author":"M Li","year":"2017","unstructured":"Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res. 2017;10(1):9. \n                    https:\/\/doi.org\/10.1186\/s13048-017-0304-9\n                    \n                  .","journal-title":"J Ovarian Res"},{"issue":"13","key":"512_CR25","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1158\/1078-0432.CCR-16-2366","volume":"23","author":"J Chatterjee","year":"2017","unstructured":"Chatterjee J, Dai W, Aziz NHA, Teo PY, Wahba J, Phelps DL, Maine CJ, Whilding LM, Dina R, Trevisan G, Flower KJ, George AJT, Ghaem-Maghami S. Clinical use of programmed cell Death-1 and its ligand expression as discriminatory and predictive markers in ovarian Cancer. Clin Cancer Res. 2017;23(13):3453\u201360. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2366\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"512_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdw625","volume":"28","author":"SJL Mesnage","year":"2017","unstructured":"Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, Leary AF. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2017;28(3):651\u20137. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw625\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"2","key":"512_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141(2):293\u2013302. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2016.03.008\n                    \n                  .","journal-title":"Gynecol Oncol"},{"issue":"2","key":"512_CR28","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","volume":"7","author":"S Darb-Esfahani","year":"2016","unstructured":"Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Johrens K. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7(2):1486\u201399. \n                    https:\/\/doi.org\/10.18632\/oncotarget.6429\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"2","key":"512_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/ERC-11-0329","volume":"19","author":"B Gyorffy","year":"2012","unstructured":"Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197\u2013208. \n                    https:\/\/doi.org\/10.1530\/ERC-11-0329\n                    \n                  .","journal-title":"Endocr Relat Cancer"},{"issue":"127","key":"512_CR30","doi-asserted-by":"publisher","first-page":"127ra137","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra137. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003689\n                    \n                  .","journal-title":"Sci Transl Med"},{"issue":"9","key":"512_CR31","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501\u20139. \n                    https:\/\/doi.org\/10.1038\/bjc.2015.101\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"6","key":"512_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10(6):910\u201323. \n                    https:\/\/doi.org\/10.1097\/JTO.0000000000000500\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"512_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1479-5876-12-151","volume":"12","author":"D Quandt","year":"2014","unstructured":"Quandt D, Jasinski-Bergner S, Muller U, Schulze B, Seliger B. Synergistic effects of IL-4 and TNFalpha on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J Transl Med. 2014;12:151. \n                    https:\/\/doi.org\/10.1186\/1479-5876-12-151\n                    \n                  .","journal-title":"J Transl Med"},{"issue":"3","key":"512_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","volume":"92","author":"H Kronig","year":"2014","unstructured":"Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU. Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol. 2014;92(3):195\u2013203. \n                    https:\/\/doi.org\/10.1111\/ejh.12228\n                    \n                  .","journal-title":"Eur J Haematol"},{"issue":"4","key":"512_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/PPO.0000000000000056","volume":"20","author":"M Sznol","year":"2014","unstructured":"Sznol M. Blockade of the B7-H1\/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014;20(4):290\u20135. \n                    https:\/\/doi.org\/10.1097\/PPO.0000000000000056\n                    \n                  .","journal-title":"Cancer J"},{"key":"512_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2016.05.001","volume":"97","author":"YJ Cha","year":"2016","unstructured":"Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. 2016;97:73\u201380. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.001\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"1","key":"512_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12282-017-0781-0","volume":"25","author":"N Tomioka","year":"2018","unstructured":"Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2018;25(1):34\u201342. \n                    https:\/\/doi.org\/10.1007\/s12282-017-0781-0\n                    \n                  .","journal-title":"Breast Cancer"},{"issue":"1","key":"512_CR38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4143\/crt.2016.066","volume":"49","author":"HI Jung","year":"2017","unstructured":"Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS, Baek MJ. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246\u201354. \n                    https:\/\/doi.org\/10.4143\/crt.2016.066\n                    \n                  .","journal-title":"Cancer Res Treat"},{"issue":"4","key":"512_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/modpathol.2016.221","volume":"30","author":"EK Enwere","year":"2017","unstructured":"Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, Kobel M, Ghatage P, Magliocco AM, Lees-Miller SP, Doll CM. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017;30(4):577\u201386. \n                    https:\/\/doi.org\/10.1038\/modpathol.2016.221\n                    \n                  .","journal-title":"Mod Pathol"},{"issue":"10","key":"512_CR40","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","volume":"19","author":"RL Korn","year":"2013","unstructured":"Korn RL, Crowley JJ. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res. 2013;19(10):2607\u201312. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2934\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"22","key":"512_CR41","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2008.16.1711","volume":"26","author":"LE Dodd","year":"2008","unstructured":"Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26(22):3791\u20136. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.1711\n                    \n                  .","journal-title":"J Clin Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0512-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0512-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T10:07:35Z","timestamp":1589882855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0512-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0512-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"1 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares that he\/she has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Although this study was not primary research involving human samples, our study was a secondary analysis regarding human subject data published in the public domain. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}